Age, mean (years) |
59.5 (39–75) |
Sex |
Male |
55 (57.3%) |
Female |
41 (42.7%) |
ECOG performance status |
0 |
35 (36.4%) |
1 |
57 (59.4%) |
2 |
4 (4.2%) |
Smoking status |
Current smokers |
56 (58.3%) |
Never smokers |
18 (18.8%) |
Former smokers |
18 (18.8%) |
Unknown |
4 (4.2%) |
Clinical stage at diagnosis |
Stage ≤ IIIB |
9 (9.4%) |
Stage IIIC |
1 (1.0%) |
Stage IV |
86 (89.6%) |
Brain metastases |
Yes |
18 (18.7%) |
No |
78 (81.3%) |
PD-L1 expression |
0% |
35 (36.5%) |
1–49% |
34 (35.4%) |
≥ 50% |
16 (16.7%) |
Unknown |
11 (11.5%) |
Biomarker testing |
EGFR mutation positive |
5 (5.2%) |
ALK re arrangement present |
0 (0.0%) |
ROS1 rearrangement present |
0 (0.0%) |
KRAS mutation present |
7 (7.3%) |
MET rearrangement present |
1 (1.0%) |
RET rearrangement present |
3 (3.1%) |
FGFR rearrangement present |
1 (1.0%) |
Docetaxel plus nintedanib line |
Second-line therapy after first line combination ChT-ICI |
24 (25%) |
Second-line therapy after first-line platinum-based ChT |
7 (7.3%) |
Third-line therapy after first-line ChT and second-line ICI |
47 (49.0%) |
Third-line therapy after first-line ICI and second-line ChT |
13 (13.5%) |
Fourth or later-lines |
3 (3.1%) |
Other¶ |
2 (2.1%) |